This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
KRT14 · Western blot design guide
KRT14 Western Blot Planning Guide
Plan a KRT14 Western blot around the catalog-observed 51.6 kDa band, image-backed A01432 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
KRT14 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 51.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Skin | |
| Negative control | Appendix |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 51.6 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated KRT14 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Breast |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A01432 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected KRT14 Western Blot Band Size?
Use the product-observed 51.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 51.6 kDa | Matches the authoritative product WB observation. |
| 51.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected KRT14 appearancePlan around 51.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 51.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 51.6 kDa from UniProt P02533; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A01432. |
| Situation | Likely cause | Next action |
|---|---|---|
| 51.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing KRT14 band
A01432 · KRT14
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for KRT14 Western blot
🧪Use Skin as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for KRT14
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skin | Reported tissue cells | High | Protein (HPA) | HPA → |
| Esophagus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cervix | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced KRT14 Western Blot Tips
Deeper troubleshooting and optimisation questions for KRT14, answered from its protein features.
Which band should guide the blot?
Use 51.6 kDa, the observation attached to the authoritative A01432 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 51.6 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for KRT14 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01432 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
KRT14 Western Blot Reagents
Human/Mouse/Rat-reactive KRT14 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Cytokeratin 14/KRT14 Antibody Picoband®
Cat # A01432
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P02533
- Human Protein Atlas — KRT14
- A01432 product record
- PMC12475053 — MCPIP3/Regnase-3 binds 14-3-3 proteins and contributes to the regulation of the cell cycle in human immortalized keratinocytes (Scientific reports, 2025)
- PMC6713913 — Keratin 14 is a novel interaction partner of keratinocyte differentiation regulator: receptor-interacting protein kinase 4 (Turkish journal of biology = Turk biyoloji dergisi, 2019)
- PMC11985182 — KRT14 knockdown reduces cisplatin resistance by lowering LRP11 expression levels in cisplatin-resistant ovarian cancer cell lines (Translational cancer research, 2025)
